Andropause or male menopause? Rationale for testosterone replacement therapy in older men with low testosterone levels

Endocrine Practice

Volumn 19, Issue 5, 2013, Pages 847-852

  Cunningham, Glenn R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; HEMOGLOBIN; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACNE; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANDROPAUSE; BLOOD VISCOSITY; BODY COMPOSITION; BONE DENSITY; CANCER RADIOTHERAPY; CANCER RISK; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CRANIOPHARYNGIOMA; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENERGY; ERYTHROCYTOSIS; FAT FREE MASS; FAT MASS; FEMUR NECK; FLUID RETENTION; FRACTURE; GLEASON SCORE; GYNECOMASTIA; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOPHYSIS TUMOR; KIDNEY FAILURE; LEAN BODY WEIGHT; LIBIDO; LIVER DISEASE; LONGITUDINAL STUDY; LOWER URINARY TRACT SYMPTOM; LUMBAR SPINE; MALE; MALE BREAST CANCER; MALE GENITAL SYSTEM FUNCTION; MOOD; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHLEBOTOMY; PHYSICAL PERFORMANCE; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATECTOMY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK FACTOR; SEXUAL FUNCTION; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDERED BREATHING; STRENGTH; TESTIS DISEASE; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; UROLOGIST;

ADULT; AGED; AGED, 80 AND OVER; ANDROPAUSE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; TESTOSTERONE; YOUNG ADULT;

EID: 84886936944     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13217.RA     Document Type: Conference Paper

References (42)

1. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81:4358-4365.
2. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670-2677.
3. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: Results from the health professionals follow-up study. Ann Intern Med. 2003;139:161-168.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
5. Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab. 1999;84:573-577.
6. Forbes GB, Reina JC. Adult lean body mass declines with age: Some longitudinal observations. Metabolism. 1970;19: 653-663.
7. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147:755-763.
8. Melton LJ III, Khosla S, Crowson CS, O?Connor MK, O?Fallon WM, Riggs BL. Epidemiology of sarcopenia. J Am Geriatr Soc. 2000;48:625-630.
9. Jette AM, Branch LG. The Framingham Disability Study: II. Physical disability among the aging. Am J Public Health. 1981;71:1211-1216.
10. Riggs BL, Wahner HW, Seeman E, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest. 1982;70:716-723.
11. Cauley JA, Ewing SK, Taylor BC, et al. Sex steroid hormones in older men: Longitudinal associations with 4.5-year change in hip bone mineral density-the osteoporotic fractures in men study. J Clin Endocrinol Metab. 2010;95:4314-4323.
12. Cooper C, Atkinson EJ, O?Fallon WM, Melton LJ III. Incidence of clinically diagnosed vertebral fractures: A population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7:221-227.
13. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood. 2004;104:2263-2268.
14. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-731.
15. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-598.
16. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011;96:2430-2439.
17. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract. 2006;60: 762-769.
18. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
19. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007; 30:911-917.
20. Tripathy D, Dhindsa S, Garg R, Khaishagi A, Syed T, Dandona P. Hypogonadotropic hypogonadism in erectile dysfunction associated with type 2 diabetes mellitus: A common defect? Metab Syndr Relat Disord. 2003;1:75-80.
21. Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26:184-190.
22. Mowat NA, Edwards CR, Fisher R, McNeilly AS, Green JR, Dawson AM. Hypothalamic-pituitary-gonadal function in men with cirrhosis of the liver. Gut. 1976;17:345-350.
23. Kamischke A, Kemper DE, Castel MA, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J. 1998;11:41-45.
24. Tengstrand B, Carlström K, Hafström I. Gonadal hormones in men with rheumatoid arthritis-from onset through 2 years. J Rheumatol. 2009;36:887-892.
25. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241-4247.
26. Cunningham GR, Toma SM. Clinical review: Why is androgen replacement in males controversial? J Clin Endocrinol Metab. 2011;96:38-52.
27. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95:639-650.
28. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
29. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56:M266-272.
30. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90:1502-1510.
31. Nair KS, Rizza RA, O?Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647-1659.
32. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20: 378-387.
33. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004;89:503-510.
34. Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58:1134-1143.
35. Liverman C, Blazer D. Testosterone and aging. Clinical research directions. Washington, DC: The National Academies Press; 2004.
36. Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639-644.
37. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25:24-28.
38. Endogenous Hormones and Prostate Cancer Collaborative Group.
39. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-183.
40. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529-534.
41. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007-3019.
42. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560-2575.